iifl-logo-icon 1

Shilpa Medicare Ltd Profit & Loss Statement

794.8
(-4.34%)
Oct 22, 2024|12:00:00 AM

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

FINANCIALS

Y/e 31 Mar( In .Cr)Mar-2021Mar-2020Mar-2018Mar-2017

Revenue

830.31

805.97

741.29

733.67

yoy growth (%)

3.02

8.72

1.03

8.56

Raw materials

-256.59

-265.56

-351.75

-368.79

As % of sales

30.9

32.95

47.45

50.26

Employee costs

-175.62

-149.27

-113.08

-91.52

As % of sales

21.15

18.52

15.25

12.47

Other costs

-171.09

-146.21

-97.39

-90.7

As % of sales (Other Cost)

20.6

18.14

13.13

12.36

Operating profit

227

244.9

179.06

182.64

OPM

27.33

30.38

24.15

24.89

Depreciation

-40.84

-34.95

-32.77

-26.65

Interest expense

-17.46

-4.32

-2.12

-2.79

Other income

33.9

11.26

23.31

19.88

Profit before tax

202.59

216.88

167.48

173.07

Taxes

-71.14

-44.14

-34.24

-41.08

Tax rate

-35.11

-20.35

-20.44

-23.73

Minorities and other

0

25.52

0

0

Adj. profit

131.44

198.26

133.23

131.98

Exceptional items

52.94

-4.54

0

-4.54

Net profit

184.39

193.71

133.23

127.44

yoy growth (%)

-4.81

45.39

4.54

12.92

NPM

22.2

24.03

17.97

17.37

Shilpa Medicare : related Articles

Top 10 stocks for today - 4th October, 2024
4 Oct 2024|08:46 AM

Here are some of the stocks that may see significant price movement today: Avenue Supermarts, Bank of Baroda, HDFC Bank, etc.

Read More
Shilpa Medicare submits new drug application with USFDA
4 Sep 2024|08:59 PM

According to the firm, the NDA submission package is based on three clinical trials, many pre-clinical investigations.

Read More
Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Securities Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedin

2024, IIFL Securities Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Securities Ltd. All rights Reserved.

Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

plus
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp